Monoclonal Antibodies to Prevent COVID

The FDA has issued emergency use authorization for AstraZeneca’s Evusheld monoclonal antibody to help prevent COVID-19 in certain adults and pediatric cases. The drug is authorized for people who are not infected with the COVID virus and who have not recently been exposed to those who are infected. Individuals must have a moderately to severely compromised immune system due to a medical condition or due to taking immunosuppressive medications or treatments and may not mount an adequate immune response to the COVID vaccine. Individuals who are not able to be fully vaccinated due to a history of severe adverse reactions to a COVID vaccine or components are also eligible.

One dose of Evusheld, given as two consecutive injections, may be effective for pre-exposure prevention for six months. Moffitt has received a limited supply of the drug, and our physicians will determine which patients should receive it based on the treatments that patients are receiving.